FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:2468 June 12, 2003 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Marcellin, P. PubMed Citation

To the Editor: I am concerned about the justification for the inclusion of a placebo group in the study by Marcellin et al. (Feb. 27 issue).¹ No statement regarding the efficacy of interferon alfa was provided, although its side effects were highlighted. Surprisingly, a study that is often cited on this topic was not referenced.² This study showed that eradication of hepatitis B e antigen (HBeAg) occurred in 33 percent of interferon-treated patients and the loss of hepatitis B virus (HBV) DNA occurred in 37 percent of interferon-treated patients, as compared with 12 percent and 17 percent of controls, respectively. . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.